Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value
- 1 September 2020
- journal article
- review article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 108 (3), 487-493
- https://doi.org/10.1002/cpt.1853
Abstract
Cancer care's sustainability is challenged by drug expenditures. In the absence of systemic change, innovation is needed to curtail drug costs. Interventional pharmacoeconomics (IVPE) utilizes clinical research to identify safe, efficacious, cost-conscious dosing regimens to extract maximum value from expensive therapies. Strategies include de-escalation of dosage, treatment duration and administration frequency, and substitution with therapeutic alternatives. In this review, we discuss how IVPE strategies have been successfully used and could be implemented going forward.This publication has 43 references indexed in Scilit:
- Lowering Medical Costs Through the Sharing of Savings by Physicians and PatientsJAMA Internal Medicine, 2014
- Redefining the primary objective of phase I oncology trialsNature Reviews Clinical Oncology, 2014
- Playing Russian Roulette With Tyrosine Kinase InhibitorsClinical Pharmacology & Therapeutics, 2012
- Lapatinib for Advanced or Metastatic Breast CancerThe Oncologist, 2012
- Flushing Oral Oncology Drugs Down the ToiletJournal of Clinical Oncology, 2011
- Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology ProductsClinical Cancer Research, 2010
- Food and Oral Antineoplastics: More Than Meets the EyeClinical Cancer Research, 2010
- Rapamycin: Something Old, Something New, Sometimes Borrowed and Now RenewedClinical Pharmacology & Therapeutics, 2007
- The Value Meal: How to Save $1,700 Per Month or More on LapatinibJournal of Clinical Oncology, 2007
- 6$prime;7$prime;-dihydroxybergamottin contributes to the grapefruit juice effect*1Clinical Pharmacology & Therapeutics, 2004